Topping the list is Keytruda, Merck’s cancer immunotherapy, which GlobalData anticipates will reach $22.2 billion in sales by 2025.
Here is the full list:
1. Keytruda ($22.2 billion)
2. Eliquis ($18.7 billion)
3. Revlimid ($12.4 billion)
4. Opdivo ($12 billion)
5. Imbruvica ($11.9 billion)
6. Humira ($10.3 billion)
7. Biktarvy ($10 billion)
8. Ibrance ($9 billion)
9. Stelara ($7.5 billion)
10. Trulicity ($7.2 billion)
More articles on pharmacy:
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September
Novant Health to open health clinics inside Walgreens
